MAPT and Alzheimer disease: CSF biomarkers, including amyloid Beta 42 (Aβ42) and Aβ40, total tau (T-tau), phosphorylated tau (P-tau) have an added value in the differential diagnosis of AD and related disorders, including mixed pathologies, atypical presentations, and in case of ambiguous clinical dementia diagnosis (72–74).